Skip to contentA
Amneal Pharmaceuticals, Inc.
A
AMRXAmneal Pharmaceuticals, Inc. Q2 2020 · 10-Q
Revenue$464.66M$464.66M+14.8% vs Q2 2019 Net Income-$24.16M-$24.16MN/M vs Q2 2019 EPS Diluted-$0.08-$0.08N/M vs Q2 2019 Gross Profit$144,237,000+37.0% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amneal Pharmaceuticals, Inc. · CIK 1723128 · Engraved from SEC EDGAR
Operating Cash Flowderived$179,241,000+749.7% Free Cash Flowderived$170,689,000+1,705.7% Margins · derivedGross margin31.0%+5.0 pt vs Q2 2019
Operating margin2.3%+7.0 pt vs Q2 2019
Net margin-5.2%−1.0 pt vs Q2 2019
ended Jun 30, 2020 · filed Aug 6, 2020 · 37 d after period end